Cadrenal Q2 net loss narrows to $3.3M; Phase 2 CAD-1005 cuts thrombotic events >25%

Cadrenal Therapeutics, Inc.

Q2 2026 net loss of $3.3M vs $3.7M in Q2 2025; R&D expenses $0.7M vs $1.1M; G&A $2.6M vs $2.7M.
Cash ~$4.2M as of early August 2026, expected to fund operations through Q1 2027; not sufficient for clinical trials.
Phase 2 CAD-1005 data at ISTH 2026 Congress in Paris showed >25% absolute reduction in thrombotic events.
Launched structured partnering process for CAD-1005, frunexian, and tecarfarin; pursuing out-licensing model.
Private placement raised ~$3.0M gross proceeds, up to ~$5.8M more if warrants fully exercised.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.